China Meheco Group shares jump after agreement to import Pfizer's COVID treatment paxlovid

Paxlovid is shown in this picture illustration
Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. REUTERS/Wolfgang Rattay/Illustration

SHANGHAI, Dec 15 (Reuters) - Shares of China Meheco Group (600056.SS) surged after the Chinese drug seller signed an agreement with Pfizer Inc (PFE.N) to import and distribute the U.S. drugmaker's oral COVID-19 treatment Paxlovid in mainland China.

Meheco shares opened up 10% in Shanghai.

Reporting by Shanghai newsroom; Editing by Jacqueline Wong

Our Standards: The Thomson Reuters Trust Principles.

Read Next